GenEdit is a pioneering biotechnology company focused on revolutionizing gene therapy and gene editing through its proprietary nanoparticle delivery technology. The company operates in the biotechnology and pharmaceutical markets, primarily serving clients in the medical and healthcare sectors who are in need of advanced gene therapy solutions. GenEdit's core technology involves engineering individual components of the CRISPR system to create a comprehensive delivery system for CRISPR-based therapeutics. This approach includes both proprietary engineering and novel nanoparticles, which enable safer and more efficient delivery options for gene knockout therapies.

Founded in 2016 with roots at the University of California, Berkeley, GenEdit has developed a proprietary polymer nanoparticle library. The company has established initial proof of concept by successfully delivering CRISPR Cas9 and gene editors to target tissues, leading to publications in key journals such as Nature Biomedical Engineering and Nature Communications. GenEdit's business model revolves around leveraging its proprietary technology to develop and commercialize gene therapies, generating revenue through partnerships, licensing agreements, and direct sales of its therapeutic solutions.

Keywords: gene therapy, CRISPR, nanoparticle delivery, biotechnology, gene editing, polymer nanoparticle library, medical, healthcare, therapeutics, proprietary technology.